semaglutide and cardiovascular outcomes in obesity without diabetes journal club patients with and prevalent heart failure: a prespecified analysis of the SELECT trial Oral Semaglutide and Cardiovascular Outcomes

Who Can Benefit from B Complex Injections

2013 Sep 15;591(18):4655-66

Provides Cardiovascular Benefits (Anti-inflammatory) Clinical trials (e.g., SUSTAIN-6, SELECT) have shown semaglutide reduces the risk of major adverse cardiovascular events (heart attack, stroke, CV death) in people with type 2 diabetes and high cardiovascular risk

Why Protein Matters More for Weight Loss on GLP-1 Research shows up to 40% of weight lost on GLP-1 medications can come from muscle, not fat which slows metabolism and raises rebound risk when medication stops

In patients with type 2 diabetes mellitus, treatment with semaglutide injection 1 mg resulted in reductions in glucose in terms of absolute change from baseline and relative reduction compared to placebo of 29 mg/dL (22%) for fasting glucose, 74 mg/dL (36%) for 2-hour postprandial glucose and 30 mg/dL (22%) for mean 24-hour glucose concentration

Effects of liraglutide on obesity-associated functional hypogonadism in men